Navidea Biopharmaceuticals Inc (PK:NAVB)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4100 Horizons Drive, Suite 205
COLUMBUS OH 43220
Tel: N/A
Website: https://www.navidea.com
IR: See website
<
Key People
Craig Dais
Chief Financial Officer, Principal Accounting Officer
   
Business Overview
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company's business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
Financial Overview
For the nine months ended 30 September 2023, Navidea Biopharmaceuticals Inc revenues decreased from $65K to $0K. Net loss applicable to common stockholders excluding extraordinary items decreased 61% to $5.3M. Revenues reflect Grant and other revenue decrease from $51K to $0K, Sales revenue decrease from $14K to $0K. Lower net loss reflects Corporate segment loss decrease of 44% to $3.7M, Diagnostics segment loss decrease of 21% to $3M.
Employees: 11 as of Mar 17, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1.59M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$10.07M as of Sep 30, 2023
Net annual income (TTM): -$8.81M as of Sep 30, 2023
Free cash flow (TTM): -$9.91M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 100,084,385 as of Nov 10, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.